Sign In
Buy LLY
$1,131.42
+6.04 (+0.537%)
At Close: Jun 05, 2026
3 Magnificent Stocks to Buy and Hold Forever
09:30am, Monday, 03'rd Feb 2025
Some people are fair-weather friends; others are lifelong. It's a similar story with stocks.
Eli Lilly Stock Before Q4 Earnings: To Buy or Not to Buy?
09:23am, Monday, 03'rd Feb 2025
Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.
With Zepbound Not Matching Expectations, Should Investors Give Up on Eli Lilly?
08:05am, Sunday, 02'nd Feb 2025
Over the past six months, Eli Lilly (LLY -1.48%) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, it is still a bit surprising, since the pharmaceu
What To Expect in the Markets This Week
05:45am, Sunday, 02'nd Feb 2025
Earnings from tech, media, and pharmaceutical firms could be in the spotlight this week, with Google parent Alphabet (GOOG, GOOGL) and Amazon (AMZN) set to report, along with Disney (DIS) and weight-l
Got $1,000? 2 Top Growth Stocks to Buy Right Now
04:38am, Sunday, 02'nd Feb 2025
Being a long-term investor isn't always easy, as you'll inevitably encounter downturns as well as the thriving bull periods that occur in a cyclical market. However, this is a far better alternative t
3 Unstoppable Stocks You Can Buy and Hold for the Rest of Your Life
08:45am, Saturday, 01'st Feb 2025
If you want stocks that you can buy and hold for not only years, but potentially the rest of your life, it's important to consider businesses that have massive growth opportunities. These are the type
Jim Cramer's week ahead: Earnings from Amazon, Alphabet, Eli Lilly, Palantir
07:03pm, Friday, 31'st Jan 2025
CNBC's Jim Cramer on Friday walked investors through an earnings-heavy week, highlighting reports from Amazon, Alphabet, Eli Lilly and Palantir, as well as a key inflation metric from the Labor Depart
New study reveals why patients stop taking GLP-1 obesity drugs
06:05pm, Friday, 31'st Jan 2025
Tricia Rodriguez, Truveta senior applied research scientist & lead study author, explains the study findings concerning why GLP-1 users stop taking the drug.
Despite greater physician pre-approval familiarity with Omvoh compared to J&J Innovative Medicine's Tremfya, gastroenterologists favor Tremfya over Omvoh for Crohn's disease Despite greater physician
As founder of Coatue Management, Philippe Laffont oversees $26.9 billion invested in more than 80 stocks, and though he buys players across many sectors, one in particular stands out. The billionaire
Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:06am, Thursday, 30'th Jan 2025
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Eli Lilly Stock's Correction Brings Opportunity
01:27pm, Wednesday, 29'th Jan 2025
I think Eli Lilly and Company's stock correction may be ending as demand for key drugs Zepbound and Mounjaro remains strong, despite recent sales guidance cuts. The company's high valuation multiples
INDIANAPOLIS--(BUSINESS WIRE)--Generation Z, Millennial donors are issue driven and technology focused, report shows.
Eli Lilly (LLY) Stock Drops Despite Market Gains: Important Facts to Note
06:50pm, Tuesday, 28'th Jan 2025
In the latest trading session, Eli Lilly (LLY) closed at $804.99, marking a -0.39% move from the previous day.
What Does the Future Hold for Eli Lilly?
08:45am, Tuesday, 28'th Jan 2025
GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S NYSE: NVO were likely the hottest medical sector story in 2024. With its offering of tirzepatide (b
